BIOEDGE

Biological EDGE

Buy Now

“Meticulous research. Penetrating analysis. A solid framework for change.”  — Dr. Michael J. Krentz

Biological EDGE

Biohacking Starts With NO

Buy Now

“I used to override my body. Now I listen. The difference is stunning.”— Michael Broder

Biohacking Starts With NO
Supplements and Compounds

Supplements and Compounds Library

Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.

AllLibraryArticlesPresentationsSpotlightsNews

Showing 145–168 of 179

Longevity.TechnologyFeb 24, 2026

FDA rewrites drug approval rules and longevity stands to gain

The FDA has shifted its drug approval standard from requiring two pivotal clinical trials to accepting one, citing advances in biological understanding, biomarker validation, and trial design sophistication. This regulatory change has direct implications for aging-related therapeutics, where slow biological processes and prevention-focused interventions have historically faced approval barriers under the two-trial requirement.

Longevity.TechnologyFeb 9, 2026

New peptide drugs on the horizon with PepLib–Lilly collab

Eli Lilly and PepLib Biotech have formed a collaboration to develop peptide-based therapeutics designed to target specific disease pathways with precision. Peptides represent a distinct therapeutic modality with applications in age-related conditions, metabolic dysfunction, and cardiovascular disease—key drivers of healthspan and lifespan limitations.

Longevity.TechnologyMar 23, 2026

Senescence consortium targets biomarker gap

The Senotherapeutics Biomarker Consortium addresses a critical gap in senescence measurement standards across academia, industry, and regulators. Standardized biomarkers are essential to advance clinical translation of senotherapeutic interventions, as current measurement heterogeneity impedes trial reproducibility and regulatory confidence.

Longevity.TechnologyFeb 4, 2026

Bexorg secures grant to speed Parkinson’s therapies

Bexorg has secured funding to validate TRPML1, a protein target for Parkinson's therapies, using preserved human brain tissue paired with AI-driven biomarker identification. This approach addresses a critical translational gap: the inability to confirm drug efficacy in human neural tissue, which has caused over 95% of CNS drug candidates to fail in clinical trials despite theoretical promise.

Nature AgingMay 12, 2026

Hypoxia-induced autophagic degradation of HIF-1α attenuates cellular aging and extends mammalian lifespan

Intervertebral discs age slowly due to selective autophagy of HIF-1α under naturally hypoxic conditions. A small molecule designed to replicate this mechanism across tissues may extend mammalian lifespan by modulating how cells respond to low-oxygen environments.

Longevity.TechnologyMar 9, 2026

Transposon’s $22m ARPA-H award to test aging-fighting drug

Transposon Therapeutics received a $22 million ARPA-H grant to study TPN-101, a drug designed to inhibit LINE-1 retrotransposon activity and slow fundamental aging processes rather than treat individual diseases. The approach targets age-related inflammation driven by DNA elements that become dysregulated with age, potentially extending healthspan across multiple conditions simultaneously.

Longevity.TechnologyMay 4, 2026

The first personalized brain repair for Parkinson’s

Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.

Longevity.TechnologyMar 2, 2026

Juvenescence advances aging drug to Phase 2 trial

Juvenescence's PAI-1 inhibitor MDI-2517 completed Phase 1 trials, demonstrating safety and tolerability for a once-daily oral therapy targeting inflammation and fibrosis—processes central to aging and age-related disease. Genetic evidence suggests PAI-1 reduction correlates with approximately 10 years of extended lifespan, positioning this mechanism as a meaningful target for aging intervention.

Nature AgingFeb 24, 2026

Senescence at the crossroads of postpartum remodeling and tumorigenesis

Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.

Nature - npj AgingMar 20, 2026

Mitorubin, berberrubine-based compounds that improve mitochondrial function, exhibit cardioprotective effects against age-related cardiac dysfunction

Mitorubin, a berberrubine-derived compound, restores mitochondrial function and protects cardiac tissue from age-related deterioration. This addresses a primary mechanism of cardiovascular aging by targeting energy production capacity at the cellular level.

Longevity.TechnologyApr 8, 2026

Epia Neuro debuts with stroke-focused BCI

Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.

Longevity.TechnologyMar 23, 2026

Unlimited Bio registers dual gene therapy trial

Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.

Wiley Aging CellFeb 17, 2026

Dynamin‐Related Protein 1‐Dependent Disruption of Mitochondrial Homeostasis Drives Blue Light‐Induced Epithelial‐Mesenchymal Transition in Retinal Aging

Blue light exposure triggers excessive mitochondrial fragmentation in retinal cells through a specific protein (Drp1), driving cellular changes associated with age-related macular degeneration. Blocking this fragmentation restores mitochondrial function and reverses the pathological transformation in both cell cultures and animal models.

Longevity.TechnologyMar 17, 2026

Evolve Science launches longevity peptide platform

Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.

Longevity.TechnologyFeb 19, 2026

Unnatural Products inks $1.7b cardiovascular disease collab with Novartis

Unnatural Products and Novartis have partnered to develop macrocyclic peptides—molecular structures between small molecules and biologics—targeting protein interactions implicated in cardiovascular disease and age-related conditions. This approach addresses a critical gap in drug development where conventional therapeutics cannot effectively engage disease-driving targets.

Nature - npj AgingMar 3, 2026

A hierarchy of causes of death in senescent C. elegans

Research in senescent C. elegans reveals a hierarchical cascade of organ system failures rather than simultaneous deterioration, with specific tissues failing in sequence as aging progresses. This finding clarifies the mechanistic order of senescent decline and suggests that interventions targeting early failures in this cascade may prevent downstream system collapse.

Peter Attia MDApr 13, 2026

#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Peptides represent a legitimate therapeutic class with demonstrated efficacy, but clinical validation is confined to a narrow subset of compounds. Most peptide applications currently marketed fall outside evidence-supported use, requiring practitioners to distinguish between established interventions and speculative applications.

Longevity.TechnologyApr 10, 2026

CorTec receives FDA breakthrough device designation

The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.

Longevity.TechnologyMar 24, 2026

Biophytis-LynxKite AI alliance broadens longevity drug pipeline

Biophytis and LynxKite are expanding their AI-driven drug discovery partnership beyond sarcopenia to build a broader platform for age-related diseases, including dry age-related macular degeneration. The alliance demonstrates a concrete application of AI to accelerate candidate identification and reduce development timelines in longevity therapeutics.

Longevity.TechnologyMar 25, 2026

Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy

Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.

Wiley Aging CellMay 20, 2026

RORA-PRNP Axis Triggers Age-Related Cataracts via Senescence

RORA, a transcription factor, exacerbates age-related cataract by targeting the prion protein (PRNP) and triggering oxidative stress-induced senescence and apoptosis in lens epithelial cells. Inhibiting RORA or blocking the RORA-PRNP axis restores cellular resilience and may offer a therapeutic target for cataract prevention and reversal.

LifeSpan.ioMar 24, 2026

BioAge Labs Provides Business Updates

BioAge Labs reported positive interim Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory cardiovascular biomarkers (hsCRP 86%, IL-6 58%, fibrinogen 30%) and brain penetration. The company is advancing toward Phase 2a trials in cardiovascular disease and expanding into ophthalmology for diabetic macular edema, positioning the compound as a multi-indication anti-inflammatory therapy.

LifeSpan.ioFeb 4, 2026

Association Between Vitamins and Slower Biological Aging

A large epidemiological analysis of 15,050 participants found that higher intake of vitamins, particularly C and B2, correlates with slower biological aging as measured by multiple aging biomarkers. The association remained significant after adjustment for socioeconomic and lifestyle factors, suggesting a direct relationship between vitamin adequacy and the rate of biological aging.

Longevity.TechnologyMar 26, 2026

Cognito and Ochsner launch brain health collaboratory

Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.